Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05559853 · ClinicalTrials.gov registry record
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
A clinical trial of Brain Metastases and Brain Metastases, Adult, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- 119
- Enrollment target
- 1
- Study location
NCT05559853: Recruiting study of Brain Metastases and Brain Metastases, Adult, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05559853 is a study of Brain Metastases and Brain Metastases, Adult that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 119 participants, below the 211-participant average among 67 other Brain Metastases trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05559853, a study of Brain Metastases and Brain Metastases, Adult, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- 119 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therapy called stereotactic radiosurgery (SRS).
Primary Outcome
Develop a rapid and robust 3D CEST-MRF pulse sequence for clinical scanners using our preclinical CEST-MRF pulse sequence as a basis by evaluating the changes of the 6 CEST-MRF parameters with and without motion. These parameters include the water T1 and T2 relaxation (T1w,T2w), amide exchange rate (ksw) and volume fraction (fs) and the semi-solid exchange rate (kssw) and volume fraction (fss).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST CEST-MRF
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2027-09-22 |
What NCT05559853 shows while recruiting
NCT05559853 is an observational study that tracks outcomes without assigning an intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 211-participant average among 67 other Brain Metastases trials with a reported enrollment target (44% lower).
The record links to 4 conditions, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which CEST-MRF is the first listed.
NCT05559853 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05559853 about?
NCT05559853 is a clinical study titled "Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment". The purpose of this study is to develop and test a new magnetic resonance imaging (MRI) technique to see if it can be used to tell the difference between tumor growth from worsening of cancer and growth from the effects of treatment in participants who have brain tumors treated with radiation therap...
What is the current status of trial NCT05559853?
This trial is currently recruiting. The enrollment target is 119 participants. The study started on 2022-09-22. Estimated completion is 2027-09-22.
What conditions does trial NCT05559853 study?
This clinical trial studies the following conditions: Brain Metastases, Brain Metastases, Adult, Metastatic Brain Tumor, Metastatic Brain Cancer.
What interventions are being tested in trial NCT05559853?
The interventions under investigation include: CEST-MRF (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05559853?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05559853 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05559853's enrollment target sits among peer trials
119 12th of 67 higher than 56 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
RECRUITING · Phase 1
-
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
RECRUITING · Phase 1
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
- NCT06930625 · 119 participants · Phase 3
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI